Moreover, anti-TEM8 CAR-T cells can serve as a potential targeted therapy for triple-negative breast cancers (TNBC). Results from Byrd et al. showed that TEM8-targeted CAR-T cells were able to concomitantly destroy TNBC tumor cells, breast cancer stem-like cells (BCSC) as well as tumor endothelial cells, and to cause regression of lung metastatic TNBC cell line-derived xenograft tumors (108). Here, ANTXR1 is linked to neoplasm.